Skip to main content
    A

    Arcus Biosciences Inc (RCUS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NYSE

    $16.88
    -0.55 (-3.16%)

    Market Cap: $2.51B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Arcus Biosciences Inc (RCUS) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Arcus Biosciences are Arcutis Biotherapeutics (ARQT), Legend Biotech (LEGN) and Aurinia Pharmaceuticals (AUPH). By market cap, Arcus Biosciences ranks 8th of the 13 companies on this page; Tarsus Pharmaceuticals (TARS) is the largest at $3.96B. The median P/E of the 4 companies with a P/E is 109.5x.

    Peer Comparison

    RCUS's ROIC of -75.9% is below the peer median of -25.2%, and its revenue growth of -65.4% is below the median of 20.2%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Arcus Biosciences (RCUS)$2.51BN/A21.5x0.0%-75.9%-65.4%0.00%
    Arcutis Biotherapeutics Inc (ARQT)$3.57B129.3x7.0x5.9%7.8%45.1%0.00%
    Legend Biotech Corp (LEGN)$3.39B266.5x2.3x-0.0%N/A32.0%0.00%
    Aurinia Pharmaceuticals Inc (AUPH)$2.11B15.2x6.4x97.7%N/A13.9%0.00%
    Tarsus Pharmaceuticals Inc (TARS)$3.96BN/A5.4x-102.9%-393.6%63.9%0.00%
    Tyra Biosciences Inc (TYRA)$1.38BN/AN/A0.0%N/A0.0%0.00%
    Xencor Inc (XNCR)$2.78BN/A13.5x-58.8%-17.3%454.9%0.00%
    Beam Therapeutics Inc (BEAM)$2.36BN/A15.0x-73.9%-29.7%-96.8%0.00%
    Forte Biosciences Inc (FBRX)$1.63BN/AN/A0.0%N/A0.0%0.00%
    MBX Biosciences, Inc. Common Stock (MBX)$2.78BN/AN/A0.0%N/A0.0%0.00%
    Celcuity LLC (CELC)$3.15BN/AN/A0.0%-25.2%0.0%0.00%
    Vericel Corp Ord (VCEL)$2.91B89.8x9.1x10.3%N/A26.5%0.00%
    Vir Biotechnology Inc (VIR)$1.71BN/A5.4x-61.0%N/A19582.0%0.00%
    Peer median$2.78B109.5x6.7x0.0%-25.2%20.2%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Arcus Biosciences, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Arcutis Biotherapeutics Inc (ARQT)
    Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
    ARQT competitors
    Legend Biotech Corp (LEGN)
    Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology...
    LEGN competitors
    Aurinia Pharmaceuticals Inc (AUPH)
    Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China.
    AUPH competitors
    Tarsus Pharmaceuticals Inc (TARS)
    Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates...
    TARS competitors
    Tyra Biosciences Inc (TYRA)
    Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and improve outcomes...
    TYRA competitors
    Xencor Inc (XNCR)
    Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed...
    XNCR competitors
    Beam Therapeutics Inc (BEAM)
    Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States.
    BEAM competitors
    Forte Biosciences Inc (FBRX)
    Forte Biosciences Inc. is a clinical-stage biopharmaceutical company in the United States. The company is headquartered in Torrance, California.
    MBX Biosciences, Inc. Common Stock (MBX)
    MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment...
    MBX competitors
    Celcuity LLC (CELC)
    Celcuity Inc., a clinical-stage biotechnology company, discovers cancer subtypes and therapeutic options for cancer patients in the United States.
    CELC competitors
    Vericel Corp Ord (VCEL)
    Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures...
    VCEL competitors
    Vir Biotechnology Inc (VIR)
    Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
    VIR competitors

    Frequently Asked Questions About RCUS

    Who are Arcus Biosciences' main competitors?

    The companies most similar to Arcus Biosciences include Arcutis Biotherapeutics (ARQT), Legend Biotech (LEGN), Aurinia Pharmaceuticals (AUPH), Tarsus Pharmaceuticals (TARS) and Tyra Biosciences (TYRA), listed from the closest match.

    Who is Arcus Biosciences' biggest competitor?

    Tarsus Pharmaceuticals (TARS) is the largest of the similar companies at $3.96B; Arcutis Biotherapeutics (ARQT) is the closest match by business profile, size, sector and industry.

    How does RCUS stock compare with its competitors?

    RCUS' P/S is 21.5x against a peer median of 6.7x; its net margin is 0.0% against a peer median of 0.0%.

    Which of Arcus Biosciences' competitors pays a higher dividend?

    Arcus Biosciences pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Arcus Biosciences bigger than its competitors?

    No. Arcus Biosciences is 8th by market cap among the 13 companies on this page; the largest is Tarsus Pharmaceuticals (TARS) at $3.96B.